TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04330833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Communication Intervention
Description: The intervention is a series of 3 guided discussions (using visual aids) between the child's primary oncology physician/nurse team and the child's parent(s) with the purpose of improving parental comprehension of the options for goals of treatment, along with the benefits and burdens of each option.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Parent Education
Description: The Enhanced Usual Care Parent Education is a series of 3 discussions between the child's primary oncology nurse and the child's parent(s) designed to control for time and attention. These discussions are focused on answering parents' questions and reviewing routine disease and treatment related information. Parents will receive a 1-hour face-to-face session every 3-4 months for a total of 3 sessions. At each session, parents choose 2-3 topics to review with the nurse.
Study: NCT03885232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: PIVOT with MI
Description: Providers in participating intervention clinics will be trained in the PIVOT-MI strategy in which a presumptive format is used to initiate the childhood vaccine recommendation with all parents followed by use of motivational interviewing (MI) with parents who voice resistance to that recommendation. Parent participants will receive PIVOT-MI.
Study: NCT01513616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: 8-week program, 3 supervised session per week

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: 8-week program, 3 supervised session per week

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: An 8-week control period (includes optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education)
Study: NCT03885232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Control
Description: Providers at participating control clinics will deliver care as usual. Parent participants will receive standard care.
Study: NCT01235923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: three times weekly Epo
Description: Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: weekly Epo
Description: Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
Study: NCT04081753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote monitoring of temperature
Description: The patient will be set up with a remote monitoring device for temperature recording and the temperature will monitored remotely
Study: NCT00744978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
Study: NCT01903551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Loco-regional catheter
Description: it is an intra-fascial catheter for realing of the drug locally
Study: NCT04000308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type 2
Description: The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wound Infiltration
Description: Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
Study: NCT01259323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN668
Description: Dose 1: REGN668 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN668
Description: Dose 2: REGN668 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN668
Description: Dose 3: REGN668 or placebo
Study: NCT05573607

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chromium
Description: A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
Study: NCT01572545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab (injection), 60 mg, administered as a single subcutaneous injection once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
Study: NCT00818662

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg
Description: 400 mg/kg bodyweight every 2 weeks for 70 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
Description: 200 mg/kg bodyweight every 2 weeks for 70 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution: Human Albumin 0.25% - 4 mL/kg
Description: Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution: Human Albumin 0.25% - 2 mL/kg
Description: Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
Study: NCT02245490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin HCl controlled release capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo capsule
Study: NCT03463343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical spine manual manipulation
Description: In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical spine mechanical manipulation
Description: In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
Study: NCT03229161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IWT-group
Study: NCT03829150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlan
Description: Dexlansoprazole MR 60 mg qd for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlan
Description: Dexlansoprazole MR 60 mg qd for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin (Amolin) 1 g bid. for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin (Amolin) 1 g bid. for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: clarithromycin (Klaricid) 500 mg bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: clarithromycin (Klaricid) 500 mg bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole (Flagyl) 500 mg bid daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole (Flagyl) 500 mg bid daily for 7 days
Study: NCT03221400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-866 Sodium
Description: PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-866 Sodium
Description: PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-866 Sodium
Description: PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-866 Sodium
Description: PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.
Study: NCT04559074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry; starting dose equivalent to current dose for patients on amlodipine at entry or at next 1-2mg dose step (according to clinical need based on the Investigator's judgement). Investigation of whether gradually increasing the dose of liquid amlodipine (can be an add-on to existing amlodipine tablets) in small increments (e.g. 1-2mg) will enable blood pressure control within the sequence 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg to a maximum of 10mg amlodipine per day.
Study: NCT02328144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days.
Study: NCT00836498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: RotaTeq
Description: Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: RotaTeq
Description: Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: RotaTeq + Placebo
Description: One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period
Study: NCT03221400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Fluorouracil 2400 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Folinic acid 400 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib
Study: NCT00425451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip
Study: NCT02152839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets
Study: NCT01614067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix acetate
Description: Subjects will receive 7 days of pre-treatment with the GnRH antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix acetate
Description: Subjects will receive 7 days of pre-treatment with the GnRH antagonist
Study: NCT00847704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assisted movement and enhanced sensation
Description: Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
Study: NCT01655550

Intervention type: OTHER
Group type: OTHER
Intervention: Withhold oral contrast
Description: The intervention is to withhold oral contrast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Withhold oral contrast
Description: The intervention is to withhold oral contrast
Study: NCT00820131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: selfgrip mesh
Description: inguinal hernia repair using a selfgrip mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lightweight mesh with suture fixation
Description: inguinal hernia repair using a lightweight mesh with suture fixation
Study: NCT00271050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: external beam radiotherapy plus 90-Y ibritumomab tiuxetan
Description: combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan
Study: NCT02159014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated group-based aerobic dance
Description: Physical activity facilitated by instructor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online, video prompted, individual aerobic dance
Description: Supported online activity intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated group-based nutritional intervention
Description: Education, skill training, access and use of NHS Change4Life Eat Well web resource

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-paced online aerobic dance activity
Description: Self paced physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual self-paced nutritional intervention
Description: Individual use of online nutritional advice resources.
Study: NCT02188212

Intervention type: DEVICE
Group type: OTHER
Intervention: NobelProcera Crown Shaded Zirconia
Study: NCT01692327

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High fat meal

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High fat meal

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High fat meal
Study: NCT03036072

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strict normothermia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delayed Rewarming
Description: Use of the servo-controlled cooling blanket for delayed rewarming to target temperature.
Study: NCT01894451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-bevacizumab
Description: 89Zr-bevacizumab is a newly developed radiotracer. Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance. The amount of the compound or drug in a radiotracer is also very small. Radiotracers are used to make images of processes that are happening in the body, but they do not affect how the body works. 89Zr-bevacizumab is made up of the drug bevacizumab and the radioactive substance zirconium-89 (89Zr). 89Zr-bevacizumab is used for an imaging procedure called positron emission tomography/computed tomography (PET/CT). 89Zr-bevacizumab-PET/CT will be performed in this study at baseline, after 2 cycles of preoperative chemotherapy and at the completion of chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Description: FDG-PET/CT scan: Pictures of your organs will be taken using a PET (Positron Emission Tomography) scanner. At the same time, a CT (computed tomography) scan will be performed. FDG, a radioactive substance similar to glucose (or sugar), will be injected into your vein using a needle prior to performing the PET/CT scan. After the injection, you will be asked to sit quietly for one hour to let the FDG absorb into the body. After this hour, you will be asked to lie flat on your back for up to 50 minutes while the PET and CT images are being taken. This FDG-PET/CT scan is part of regular cancer care. If you have had this test within 14 days of study enrollment, you may or may not have to have this test repeated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: • MRI Scan: MRI (Magnetic Resonance Imaging) scans of the breast will be taken. You will receive an injection of a dye before the MRI. You will be asked to lie flat on your back in the scanner for up to 30 minutes for pictures to be taken. This MRI scan is part of regular cancer care. If you have had this test within 14 days of study enrollment , you may or may not have to have this test repeated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsies
Description: Tumor biopsies: Prior to starting your treatment, a radiologist will use breast MRI or ultrasound imaging to localize an area of your tumor in the breast for a research biopsy. The biopsy procedure is done in an outpatient setting using a done using a needle to obtain tissue. A local anesthetic will be given to minimize any pain; however, after the procedure you can expect some discomfort and possible bruising. This biopsy is part of research.
Study: NCT02482623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia Symptom Management at Home Program
Description: The DSM-H is a multi-modal interprofessional intervention that includes: 1. intensive training of clinician mentors; 2. disseminated online training for Registered Nurses, Physical Therapists, Occupational Therapists; 3. implementation of evidence-based care plans, assessment instruments, and teaching handouts.
Study: NCT03382392

Intervention type: OTHER
Intervention: Assesment of REE in ALS patients compared to control populations and to compare six formulas commonly used to predict REE.
Study: NCT04108533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-Based Support
Description: Text-based breastfeeding support as described in arm/group descriptions
Study: NCT00541489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxcinod
Description: 750 mg, bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 500 mg, bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: bid
Study: NCT02111850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)
Description: Day 0: cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)
Description: Day 0: cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5 % in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5 % in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m\^2 /day intravenous piggy-back (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m\^2 /day intravenous piggy-back (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
Study: NCT04211051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LungBrella marker implantation and VATS partial lobe resection
Description: The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
Study: NCT01302587

Intervention type: DRUG
Intervention: Albuterol
Description: Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.